The World Health Organization defines a rare disease as having a prevalence of 65 or less per 100,000 individuals. It recognizes some 5,500 rare diseases, the majority being of genetic origin and often life-threatening. Medical research has yielded significant drug development for the treatment of rare diseases, increasing life expectancy and improving quality of life. However, […]
An article outlining the implications of a single-payer universal pharmacare system was the most-read story on BenefitsCanada.com this week. Here are the top five human resources, benefits, pension and investmnet stories of the past week: 1. Sounding Board: What plan sponsors should know about pharmacare 2. Meet the 2024 Workplace Benefits Awards judges 3. Mental-health claims by Canadians up […]
An article detailing a stark increase in the use of obesity medications among Canadian employer-sponsored benefits plan members was the most-read article on BenefitsCanada.com this week. Here are the top five human resources, benefits, pension and investment stories of the past week: 1. Claims for obesity drugs increased 42% in 2023, 92% since 2020: report 2. How […]
An article on legal challenges filed against the federal government’s hybrid work mandate for public service employees was the most-read story on BenefitsCanada.com this week. Here are the top five human resources, benefits, pension and investment stories of the past week: 1. Unions representing federal public service workers file legal challenges against hybrid work mandate 2. Expert […]
While the concept behind the federal government’s universal pharmacare plan is well intentioned, the program would make a larger impact for employers by focusing on high-cost and specialty drugs, says Pam Martin, vice-president and senior consultant at Baynes & White Inc. In theory, the way that the government is rolling out the program in small […]
Many Canadians living with asthma are experiencing poor control over their symptoms, impacting the workplace, said Anjila Arora, director of pharmaceutical benefits at Sun Life Financial Inc., during Benefits Canada’s 2023 Face to Face Drug Plan Management Forum. Between 53 and 90 per cent of asthmatic Canadians meet at least one criteria for poor control […]
It’s important for private payers and employers to be nimble and innovative to support plan members seeking access to novel drugs and treatments by addressing common hurdles within their own drug plans, said John Adams, chair of the board of directors for patient advocacy group Best Medicines Coalition, during a session at Benefits Canada’s 2023 Face […]
A story on mental-health themes and challenges for 2024 was the most-read story on BenefitsCanada.com this week. Here are the top five human resources, benefits, pension and investment stories of the past week: 1. Expert panel: Employers taking preventative, holistic approach to employee mental health in 2024 2. AI holds uncapped potential for pension plan sponsors’ administration, communications: […]
The 10 highest-cost drugs reimbursed by public drug plans in Canada in the 2021/22 fiscal year were all rare disease treatments with annual treatment costs of more than $250,000, according to a new report by the Patented Medicine Prices Review Board. It found the increased use of high-cost drugs continued to be the main factor […]
More than half (58 per cent) of global insurers say they anticipate higher health benefits costs over the next three years, with the average global cost trend projected to increase by 9.9 per cent in 2024, according to a new survey by WTW. The survey, which polled more than 260 insurers representing 66 countries, found […]